| DB ID | MyCo_1578 |
| Title | Prospective monitoring for invasive aspergillosis using galactomannan and polymerase chain reaction in high risk pediatric patients |
| Year | 2009 |
| PMID | 19855303 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | High-risk leukemia (HRL) / Allogenic hematopoietic cell transplant (HCT) |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | The Committee on Clinical Investigations at CHLA (Institutional Review Board) approved the conduct of this study (Institute of Children’s Hospital, Los Angeles). |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomann |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | California, Los Angeles |
| Cohort | The study population was comprised of consecutive patients treated at Children’s Hospital Los Angeles (CHLS) between March 2006 and July 2007 and deemed to be at increased risk of developing IA secondary to expected prolonged neutropenia>10 days, steroid use (>2 wk) and/ or allogenic hematopoietic stem cell transplantation. There were 69 patients enrolled on study. All except one had at least 2 GM specimens collected during the study period. |
| Cohort No. | 69 |
| Age Group | None |
| P Value | None |
| Sensitivity | 0.657 |
| Specificity | 0.872 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive aspergillosis (IA) infections continue to have a high morbidity and mortality in immunocompromised populations.1–4 Outcomes are improved when IA is diagnosed early, prompting the initiation of appropriate antifungal therapy.5–8 However, early diagnosis is hampered by nonspecific findings, rarity of positive blood cultures, and concerns about potential morbidity from invasive procedures, which are often necessary to establish tissue diagnosis. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | GM ELISA Kit (Platelia Aspergillus EIA; BioRad Laboratories), QIAamp DNA Blood Mini Kit (Qiagen) |
| Assay Data | None |
| Validation Techniques used | ELISA, PCR |
| Up Regulation Down Regulation | None |
| Sequence Data | None |
| External Link | None |
